A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

This study is testing a drug called LM-302 in combination with other cancer treatments for people with advanced stomach or gastrointestinal cancers that express a protein called CLDN18.2. The study is for patients whose cancer has not responded to standard first-line treatment. **You may be eligible if...** - You are aged 18–80 and in good general health (ECOG 0–1) - You have been diagnosed with an advanced gastrointestinal tumor (confirmed by biopsy) - Your cancer tests positive for CLDN18.2 (a specific protein marker) - Your first-line treatment has failed or you could not tolerate it - You have at least one measurable tumor lesion - Your organs (liver, kidneys, blood counts) are functioning adequately - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - Your cancer does not express CLDN18.2 - You have not yet received first-line treatment (except in specific circumstances) - Your organ function does not meet study requirements Talk to your doctor to see if this trial is right for you.